Elixophyllin

Acute Bronchitis, Bronchial Spasm, Asthma + 8 more
Treatment
7 FDA approvals
20 Active Studies for Elixophyllin

What is Elixophyllin

TheophyllineThe Generic name of this drug
Treatment SummaryTheophylline is a medication derived from tea that works as a diuretic, muscle relaxant, and bronchodilator. It also stimulates the heart and central nervous system. Theophylline works by blocking certain enzymes and activating histone deacetylase. It is mainly used to treat asthma, breathing problems, and chronic obstructive pulmonary disease (COPD), and is sold under the brand names Uniphyl and Theochron.
Elixophyllinis the brand name
Elixophyllin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Elixophyllin
Theophylline
1979
114

Approved as Treatment by the FDA

Theophylline, commonly known as Elixophyllin, is approved by the FDA for 7 uses like Chronic Bronchitis and Lung Disorder .
Chronic Bronchitis
Lung Disorder
Asthma
Asthma
Bronchitis, Chronic
Bronchoconstriction
Lung Diseases

Effectiveness

How Elixophyllin Affects PatientsTheophylline is a medication used to treat asthma and bronchial spasms, and is chemically similar to caffeine and theobromine. It works by relaxing the airways (to reduce bronchospasms) and by reducing sensitivity of the airways to triggers.
How Elixophyllin works in the bodyTheophylline works by relaxing the muscles of the airways and reducing their sensitivity to allergens and other irritants. It does this by blocking enzymes that break down molecules responsible for muscle contraction, as well as blocking a receptor that can cause airway constriction. In addition, it can reduce inflammation by preventing proteins involved in the inflammatory process from being made.

When to interrupt dosage

The prescribed dosage of Elixophyllin is contingent upon the identified condition, such as Bronchodilation, Bronchoconstriction and Chronic Obstructive Pulmonary Disease (COPD). The dose is subject to the technique of administration as specified in the table below.
Condition
Dosage
Administration
Chronic Obstructive Pulmonary Disease
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Bronchitis, Chronic
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Asthma
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Airway secretion clearance therapy
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Acute Bronchitis
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Bronchial Spasm
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Emphysema
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Bronchoconstriction
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Lung Diseases
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Bronchodilation
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous
Bronchitis, Chronic
, 8.0 mg/mL, 0.8 mg/mL, 1.6 mg/mL, 300.0 mg, 200.0 mg, 100.0 mg, 400.0 mg, 450.0 mg, 600.0 mg, 50.0 mg, 250.0 mg, 500.0 mg, 125.0 mg, 70.0 mg, 140.0 mg, 118.0 mg, 2.0 mg/mL, 4.0 mg/mL, 3.2 mg/mL, 175.0 mg, 65.0 mg, 75.0 mg, 350.0 mg, 130.0 mg, 0.4 mg/mL, 7.0 mg/mL
, Oral, Solution, Solution - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Elixir, Elixir - Oral, Syrup, Syrup - Oral, Capsule - Oral, Capsule, Kit, Injection, Injection - Intravenous, Solution - Intravenous

Warnings

There are 20 known major drug interactions with Elixophyllin.
Common Elixophyllin Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Theophylline.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Theophylline.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Theophylline.
Bendamustine
Major
The metabolism of Bendamustine can be decreased when combined with Theophylline.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Theophylline.
Elixophyllin Toxicity & Overdose RiskSigns of an overdose on this drug include seizures, abnormal heart rhythms, and stomach issues.

Elixophyllin Novel Uses: Which Conditions Have a Clinical Trial Featuring Elixophyllin?

280 clinical trials are presently in progress to assess the potential of Elixophyllin in providing Bronchodilation, ameliorating Chronic Bronchitis and managing Asthma.
Condition
Clinical Trials
Trial Phases
Asthma
92 Actively Recruiting
Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3
Chronic Obstructive Pulmonary Disease
77 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4
Airway secretion clearance therapy
0 Actively Recruiting
Bronchoconstriction
0 Actively Recruiting
Bronchodilation
0 Actively Recruiting
Emphysema
4 Actively Recruiting
Phase 2, Not Applicable
Bronchitis, Chronic
0 Actively Recruiting
Acute Bronchitis
1 Actively Recruiting
Not Applicable
Bronchitis, Chronic
0 Actively Recruiting
Lung Diseases
5 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Bronchial Spasm
0 Actively Recruiting

Patient Q&A Section about elixophyllin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Elixophyllin used for?

"If you want to avoid wheezing and shortness of breath, you need to use this medication regularly. It's a type of drug called a xanthine, which relaxes the muscles around your airways so you can breathe more easily. Using it also reduces the lungs' reaction to irritants."

Answered by AI

What are the side effects adverse reactions and drug interactions related to Elixophyllin?

"The following list outlines some of the side effects that have been associated with theophylline use:

-Nausea -Vomiting -Headache -Insomnia

These side effects are generally mild when peak serum theophylline concentrations are <20 mcg/mL."

Answered by AI

What drugs contain theophylline?

"The medication elixophyllin is used to treat asthma and other respiratory conditions. It is available in oral and inhalation forms. Other medications in this class include Norphyl, Phyllocontin, Quibron-T, Quibron-TSR, Theo-24, TheoCap, and Theochron."

Answered by AI

What is the generic name for theophylline?

"Uniphyl and Theochron are brand names for theophylline, a medication used to treat asthma, bronchospasm, and COPD."

Answered by AI

Clinical Trials for Elixophyllin

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Have you considered Elixophyllin clinical trials? We made a collection of clinical trials featuring Elixophyllin, we think they might fit your search criteria.Go to Trials
Image of The University of Tennessee Graduate School of Medicine in Knoxville, United States.

Nebulizer vs Inhaler for COPD

18+
All Sexes
Knoxville, TN
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted). The investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination administered by nebulizer will improve hyperinflation (increase in inspiratory capacity and reduction in residual volume) and reduce symptoms related to COPD to a greater extent than LAMA/LABA therapy given by a DPI. The study aims to demonstrate the following: 1. Compare the values of inspiratory capacity (IC) and residual volume (RV) in patients receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer 2. Compare patient reported outcomes (COPD Assessment Test (CAT score), Baseline/Transition Dyspnea Index (BDI/TDI) and the St. George Respiratory Questionnaire (SGRQ) in symptomatic patients with COPD receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer
Phase 4
Recruiting
The University of Tennessee Graduate School of MedicineTheravance Biopharma
Have you considered Elixophyllin clinical trials? We made a collection of clinical trials featuring Elixophyllin, we think they might fit your search criteria.Go to Trials
Have you considered Elixophyllin clinical trials? We made a collection of clinical trials featuring Elixophyllin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security